MAPESolutions is constantly improving to be recognized, throughout Latin America, as the main company in the segment to present innovative solutions aimed at the sustainability of health systems.
Opening Hours
Mon – Fri: 08.00 – 17.00
E-mail: contato@mapesolutions.com
Copyright © Mapes - Powered by Traction
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
When a drug is developed, the company that owns the patent retains control over who can make or sell it. But this patent has an expiration date and, when it expires, other companies can develop a generic product with the same active ingredient – and market it at a more affordable price. This happens with biological medicines as well, but as they are much more complex than conventional chemical medicines, it is not possible to develop an identical product. This “generic” version of a biological, therefore, is called a biosimilar medicine.
Although not identical to the original biological medicine, the biosimilar does not lose anything in quality, safety and efficacy and, at the same time, it manages to be produced at lower costs, which makes it more accessible to patients. This encourages competition in the marketplace, which tends to lower not only the final price of the product, but also the production costs – both of biosimilars and original biologicals – providing easier access to this type of medicine.
Approval process for biosimilar medicines
As it is not possible to produce a biosimilar identical to the original biological, this type of drug undergoes a rigorous approval system by ANVISA (National Health Surveillance Agency), which includes the following studies:
The amount of data requested varies according to the type of drug submitted for analysis, but studies on biosimilars are usually shorter and smaller than those on reference biologicals.
Do you want to know how MAPESolutions contributed to the strategy for accessing immunobiological drugs through a Focus Group? Download the Case Immunobiologicals right now.Case Immunobiological.
Recent Posts
Popular Post
Como a tecnologia pode garantir o conceito
20/10/2021Importance of monitoring the clinical outcome of
15/03/2021The importance of economic evaluation in the
19/01/2021Popular Categories
Archives